Serotonin syndrome

Annals of Emergency Medicine

Volumn 28, Issue 5, 1996, Pages 520-526

  Martin, T G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CHLORPROMAZINE; CLOMIPRAMINE; CLORGYLINE; CYPROHEPTADINE; DANTROLENE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUVOXAMINE MALEATE; HALOPERIDOL; METHYSERGIDE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PETHIDINE; PHENELZINE; PROPRANOLOL; SEROTONIN 1A ANTAGONIST; SEROTONIN 2 ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGITATION; AUTONOMIC DYSFUNCTION; COMA; CONFUSION; DELIRIUM; DEPRESSION; DOSE RESPONSE; DRUG INTOXICATION; EARLY DIAGNOSIS; HALLUCINATION; HUMAN; LETHALITY; MANIA; MENTAL DISEASE; MUTISM; NEUROLEPTIC MALIGNANT SYNDROME; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; REVIEW; SEROTONIN SYNDROME;

EID: 0029926503     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-0644(96)70116-6     Document Type: Review

References (94)

1. DJ Borys SC Setzer LJ Ling Acute fluoxetine overdose: A report of 234 cases Am J Emerg Med 10 1992 115 120
2. LLP Simonsen Top 200 Drugs: Rx prices still moderating as managed care grows Pharm Times April 1995 17 23
3. SM Hess W Doepfner Behavioral effects and brain amine contents in rats Arch Int Pharmacodyn Ther 134 1961 89 99
4. DC Grahame-Smith Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan J Neurochem 18 1971 1053 1066
5. JG Sinclair Dextromethorphan-monoamine oxidase inhibitor interaction in rabbits J Pharm Pharmacol 25 1973 803 808
6. JA Oates A Sjoerdsma Neurologic effects of tryptophan in patients receiving monoamine oxidase inhibitor Neurology 10 1960 1076 1078
7. B Smith DJ Prockop Central-nervous system effects of ingestion of L-tryptophan by normal subjects N Engl J Med 267 1962 1338 1341
8. RM Cohen D Pickar DL Murphy Myoclonus-associated hypomania during MAO-inhibitor treatment Am J Psychiatry 137 1980 105 106
9. TR Insel BF Roy RM Cohen Possible development of the serotonin syndrome in man Am J Psychiatry 139 1982 945 955
10. RS Mitchell Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis Ann Intern Med 42 1955 417 424
11. H Sternbach The serotonin syndrome Am J Psychiatry 148 1991 705 713
12. DW Nierenberg M Semprebon The central nervous system serotonin syndrome Clin Pharmacol Ther 53 1993 84 88
13. KA Sporer The serotonin syndrome Drug Safety 13 1995 94 104
14. RA Bodner T Lynch L Lewis Serotonin syndrome Neurology 45 1995 219 223
15. R Ohman O Spigset Serotonin syndrome induced by fluvoxamine-lithium interaction Pharmacopsychiatry 26 1993 263 264
16. H Kojima T Terao R Yoshimura Serotonin syndrome during clomipramine and lithium therapy [letter] Am J Psychiatry 150 1993 1897
17. RM Tackley B Tregaskis Fatal disseminated intravascular coagulation following a monoamine oxidase inhibitor/tricyclic interaction Anaesthesia 42 1987 760 763
18. F Miller R Friedman J Tanenbaum Disseminated intravascular coagulation and acute myoglobinuric renal failure: A consequence of the serotonin syndrome J Clin Psychopharmacol 11 1991 277 279
19. GM Goodwin RJ De Souza AR Green The pharmacology of the behavioral and hyperthermic responses of rats to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) Psychopharmacology 91 1987 506 511
20. J Yamada Y Sugimoto K Horisaka The behavioral effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice Eur J Pharmacol 154 1988 299 304
21. SC Risch CB Nemeroff Neurochemical alterations of serotonergic neuronal systems in depression J Clin Psychiatry 53 1992 3 7
22. RA Glennon NA Darmani BR Martin Multiple populations of serotonin receptors may modulate the behavioral effects of serotonergic agents Life Sci 48 1991 2493 2498
23. AJ Sleight CA Marsden KF Martin Relationship between extracellular 5-hydroxytryptamine and behavior following monoamine oxidase inhibition and L-tryptophan Br J Pharmacol 93 1988 303 310
24. MD Tricklebank C Forler JR Fozard The involvement of subtypes of the 5-HT receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2(di-n-propylamino) tetralin in the rat Eur J Pharmacol 106 1984 271 282
25. AR Green DG Grahame-Smith The role of brain dopamine in the hyperactivity syndrome produced by increased 5-HT synthesis in rats Neuropharmacology 13 1974 949 959
26. DJ Heal AR Green DJ Boullin Single and repeated administration of neuroleptic drugs to rats: Effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-dopa Psychopharmacology 49 1976 287 300
27. EK Silbergeld RE Hurska Lisuride and LSD: Dopaminergic and serotonergic interactions in the serotonin syndrome Psychopharmacology 65 1979 233 257
28. JA Lieberman JM Kane R Reife Neuromuscular effects of monoamine oxidase inhibitors J Clin Psychopharmacol 5 1985 221 228
29. CA Marsden G Curson The contributions of tryptamine to the behavioural effects of L-tryptophan in tranylcypromine-treated rats Psychopharmacology 57 1978 71 76
30. CA Marsden G Curson The role of tryptamine in the behavioural effects of tranylcypromine + L-tryptophan Neuropharmacology 18 1979 159 164
31. AR Green MBH Youdim Effects of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcypromine on 5-hydroxytryptamine concentration in rat brain and hyperactivity following subsequent tryptophan administration Br J Pharmacol 55 1975 415 422
32. LH Price DS Charney GR Heninger Serotonin syndrome [letter] Am J Psychiatry 149 1992 1116 1117
33. EC Muly W McDonald D Steffens Serotonin syndrome produced by a combination of fluoxetine and lithium [letter] Am J Psychiatry 150 1993 1565
34. RJ Goldberg M Huk Serotonin syndrome from trazodone and buspirone [letter] Psychosomatics 33 1992 235 236
35. MJ Smilkstein SC Smolinske BH Rumack A case of MAO inhibitor/MDMA interaction: Agony after ecstasy Clin Toxicol 25 1987 149 159
36. M Lejoyeux F Fineyre J Andes The serotonin syndrome [letter] Am J Psychiatry 149 1992 1410 1411
37. A Lenzi S Raffaelli D Marazziti Serotonin syndrome-like symptoms in a patient with obsessive-compulsive disorder, following inappropriate increase in fluvoxamine dosage Pharmacopsychiatry 26 1993 100 101
38. O Spigset T Mjorndal O Loveheim Serotonin syndrome caused by a moclobemide-clomipramine interaction BMJ 306 1993 248
39. TR Brodribb M Downey PJ Gilbar Efficacy and adverse effects of moclobemide [letter] Lancet 343 1994 475
40. N Rivers B Horner Possible lethal interaction between Nardil and dextromethorphan Can Med Assoc J 103 1970 85
41. BP Skop JA Finkelstein TR Mareth The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease Am J Emerg Med 12 1994 642 644
42. D Meyer V Halfin Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: A case report and critical review J Clin Psychpharmacol 1 1981 319 321
43. GL Zornberg JA Bodkin BM Cohen Severe adverse interaction between pethidine and selegiline [letter] Lancet 337 1991 264
44. TE Hansen K Dieter GA Keepers Interaction of fluoxetine and pentazocine Am J Psychiatry 147 1990 949 950
45. S Kalsner M Nickerson Mechanisms of cocaine potentiation of responses to amines Br J Pharmacol 35 1969 428 439
46. SG Tordoff JF Stubbing SPK Linter Delayed excitatory reaction following interaction of cocaine and monoamine oxidase inhibitor (Phenelzine) Br J Anaesth 66 1991 516 518
47. JP Feighner WF Boyer DL Tyler Adverse consequences of fluoxetine-MAOI combination therapy J Clin Psychiatry 51 1990 222 225
48. MT Pato DL Murphy CL DeVane Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation [letter] J Clin Pharmacol 11 1991 224 225
49. JD Coplan JM Gorman Detectable levels of fluoxetine metabolites after discontinuation: An unexpected serotonin syndrome [letter] Am J Psychiatry 150 1993 837
50. HYT Yang NH Neff The monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines J Pharmacol Exp Ther 189 1974 733 740
51. DG Wells AR Bjorksten Monoamine oxidase inhibitors revisited Can J Anaesth 36 1989 66 74
52. E Ciocatto G Fagiano GL Bava Clinical features and treatment of overdosage of monoamine oxidase inhibitors and their interaction with other psychotropic drugs Resuscitation 1 1972 69 72
53. N Mendis CMB Pare M Sandler Is the failure of L-deprenyl, a selective monoamine oxidase B inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology 73 1981 87 90
54. PJ Neuvonen S Pohjola-Sintonen U Tacke Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses [letter] Lancet 342 1993 1419
55. CJ Fowler SB Ross Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmalogical and clinical properties Med Res Rev 4 1984 323 358
56. B Blackwell Monoamine oxidase inhibitor interactions with other drugs J Clin Psychopharmacol 11 1991 55 59
57. DL Murphy S Lipper S Slater Selectivity of clorgyline and pargyline as inhibitors of monamine oxidases A and B in vivo in man Psychopharmacology 69 1979 129 132
58. O Suchowersky J deVries Possible interactions between deprenyl and prozac [letter] Can J Neurol Sci 17 1990 352 353
59. PM Graham JM Potter JW Paterson Combination monoamine oxidase inhibitor/tricyclic antidepressant interaction [letter] Lancet 2 1982 440
60. WF Kuhn PJ Light SC Kuhn Stiff-man syndrome: Case report Acad Emerg Med 2 1995 735 738
61. J Rosenberg P Pentel S Pond Hyperthermia associated with drug intoxication Crit Care Med 14 1986 964 969
62. SL Levenson Neuroleptic malignant syndrome Am J Psychiatry 142 1985 1137 1142
63. D Heyland M Sauve Neuroleptic malignant syndrome without the use of neuroleptics Can Med Assoc J 145 1991 817 819
64. M Halman DS Goldbloom Fluoxetine and neuroleptic malignant syndrome Biol Psychiatry 28 1990 518 521
65. A Lazarus Therapy of neuroleptic malignant syndrome Psychiatric Dev 1 1986 19 30
66. MR Rosenberg M Green Neuroleptic malignant syndrome: Review of response to therapy Arch Intern Med 149 1989 1927 1937
67. D Nierenberg M Disch E Manheimer Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome Clin Pharmacol Therap 50 1991 580 586
68. SS Kline LS Mauro DM Scala-Barnett Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death Clin Pharmacol 8 1989 510 514
69. AN Singh J Maguire Neuroleptic malignant syndrome: A misnomer? [letter] Br J Psychiatry 151 1987 863 865
70. G Beaumont Drug interactions with clomipramine (Anafranil) J Int Med Res 1 1973 480 484
71. MJ Kuisma Fatal serotonin syndrome with trismus [letter] Ann Emerg Med 26 1995 108
72. DA Asch RM Parker The Libby Zion case: One step forward or two steps backward? N Engl J Med 318 1988 771 775
73. JA Henry Serotonin syndrome [letter] Lancet 343 1994 607
74. G Braitberg Serotonin syndrome [letter] 160 1994 527 528
75. I Lucki MS Nobler A Frazer Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat J Pharmacol Exp Ther 1 1984 133 139
76. RM Stewart A Campbell G Sperk Receptor mechanisms in increased sensitivity to serotonin agonists after dihydroxytryptamine shown by electronic monitoring of muscle twitches in the rat Psychopharmacology 60 1979 281 289
77. HL Klawans Jr C Goetz WJ Weiner 5-Hydroxytryptophan induced myoclonus in guinea pigs and the possible role of serotonin in infantile myoclonus Neurology 23 1973 1234 1240
78. JFW Deakin AR Green The effects of putative 5-hydroxytryptamine antagonists on the behavior produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats Br J Pharmacol 64 1978 201 209
79. M Weinstock C Weiss S Gitter Blockade of 5-hydroxytryptamine receptors in the central nervous system by beta-adrenoreceptor antagonists Neuropharmacology 16 1977 273 276
80. JS Sprouse GK Aghajanian (-)-Propranolol blocks the inhibition of serotonergic dorsal raphe cell firing by 5-HT1A selective agonists Eur J Pharmacol 128 1986 295 298
81. JT Shepherd B Whiting Beta-adrenergic blockade in the treatment of M.A.O.I. self-poisoning [letter] Lancet 2 1974 1021
82. BH Guze LR Baster Serotonin syndrome: Case responsive to propranolol [letter] J Clin Psychopharmacol 6 1986 119 120
83. B Klee MH Kronig Case report of probable sertraline-induced akathisia Am J Psychiatry 150 1993 986 987
84. R Lappin E Auchincloss Treatment of serotonin syndrome with cyproheptadine N Engl J Med 331 1994 1021 1022
85. P Jenner JA Pratt DC Marsden Mechanisms of action of clonazepam in myoclonus in relation to effects of GABA and 5-HT Adv Neurol 43 1986 629 643
86. S Gimenez-Roldan D Mateo JG Yebenes Clinical, biochemical and pharmacological observation in a patient with postasphyxic myoclonus: Association to serotonin hyperactivity Clin Neuropharmacol 11 1988 151 160
87. SR Snider CS Hutt B Stein Increase in brain serotonin produced by bromocriptine Neurosci Lett 1 1975 237 241
88. SR Snider C Hutt B Stein Correlation of behavioural inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover J Pharm Pharmacol 28 1976 563 566
89. CS Hutt SR Snider S Fahn Interaction between bromocriptine and levodopa Neurology 27 1977 505 510
90. DJ Coons FJ Hillman RW Marshall Treatment of neuroleptic malignant syndrome with dantrolene sodium: A case report Am J Psychiatry 139 1982 944 945
91. TJ Meredith D Jacobsen JA Haines Naloxone, Flumazenil and Dantrolene as Antidotes , vol I, IPCS/CEC Evaluation of Antidotes Series 1991 University Press Cambridge, England
92. R Kaplan N Feinglass W Webster Phenelzine overdose treated with dantrolene sodium JAMA 255 1986 642 644
93. K Nisijima T Ishiguro Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study Biol Psychiatry 33 1993 45 48